Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Oct 22 | 2020Thoughts on Ziopharm's TCR-T Programs; Ziopharm at Jefferies Cell Therapy Summit Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T Oct 16 | 2020Allogene and MD Anderson Announce a 5-Year Collaboration to Develop Allogeneic CAR-TsAccess Free Blast
Free
Posted in: CAR-T, CD19 Oct 16 | 2020CHMP Adopts Positive Opinion for Gilead’s Tecartus in r/r Mantle Cell LymphomaAccess Free Blast
Free
Posted in: Autologous, CD19 Oct 16 | 2020Thoughts on Ide-cel Data Presentation at ASH 2020; FDA Unlikely to Hold an Ide-cel Advisory Committee Meeting; Summary of bluebird at Jefferies Cell Therapy SummitAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T Oct 15 | 2020Precision BioSciences Wins Patent Challenge Relating to CAR-T EngineeringAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Oct 14 | 2020JNJ-4528 US Filing Anticipated in Q4 2020; JNJ Q3 2020 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Oct 13 | 2020Ziopharm´s RPM Allogeneic CD19 CAR-T Trial Started Enrollment; Q2 2020 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 09 | 2020Thoughts on Gilead's sBLA Submission for Yescarta in r/r iNHL (ZUMA-5)Access Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Oct 02 | 2020Precision Biosciences Highlights First Patient Dosed with BCMA CAR-T PBCAR269A; PBCAR0191 Clinical Updates Delayed to YE; Q2 2020 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 30 | 2020Legend Biotech Highlights FDA Filing of Cilta-Cel by YE 2020; Q2 2020 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA Sep 22 | 2020BMS and bluebird bio Receive Priority Review for Ide-cel; PDUFA Projected Around March 27, 2021Access Free Blast
Free
Posted in: Autologous, CD19, CD22 Sep 21 | 2020Updated AUTO3 Ph1/2 ALEXANDER Results; ESMO 2020 Investor Call SummaryAccess Free Blast
Free
Posted in: CAR-T, CD123, CD22, CS1 Sep 18 | 2020Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Sep 08 | 2020Thoughts on Autolus's CAR-T Program; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Sep 04 | 2020Gilead Highlights No Impact of COVID-19 on Yescarta Sales; Two New LCM Initiatives for Yescarta; Q2 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 03 | 2020bluebird bio Highlights Ide-cel Resubmission; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Sep 01 | 2020Thoughts on Allogene’s AlloCAR Program; Q2 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: BCMA, CAR-T, CD19 Sep 01 | 2020BMS Highlights Ide-cel FDA Re-submission; Q2 2020 Earnings CallAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Aug 31 | 2020Thoughts on Gilead's Recent FDA Approval for Tecartus (KTE-X19) in R/R Mantle Cell LymphomaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jul 30 | 2020BMS and bluebird bio Resubmit Ide-cel to FDA; Dynamic H1 2021 BCMA Launch Environment Expected with JanssenAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.